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Only a limited number of the older cytotoxic drugs induce more
than 15% objective responses as single-agents in patients with
advanced non-small-cell lung cancer (NSCLC). One of these is
epirubicin, the 4¢ epimer of the anthracycline antibiotic doxoru-
bicin. High-dose epirubicin (³ 120 mg m–2) as a single agent has
shown tumour response rates of 25–36% (Wils et al, 1990; Smit et
al, 1992). The major acute dose-limiting toxicity (DLT) of anthra-
cyclines is myelosuppression, the most important chronic DLT is
cardiotoxicity manifested by an irreversible cardiomyopathy
(Plosker and Faulds, 1993). In earlier studies epirubicin has
demonstrated less bone marrow and cardiac toxicity compared to
doxorubicin (Launchbury and Habboubi, 1993). With the many
new cytotoxic drugs now available several combination regimens
are possible. One of these new active drugs in NSCLC is gem-
citabine, a nucleoside analogue, which as a single-agent showed a
response rate of 22% (Abratt et al, 1994; Gatzemeier et al, 1996).
Toxicity of gemcitabine is generally mild with thrombocytopenia
as the DLT. In combination regimens, gemcitabine 1000 mg m–2
intravenously (i.v.) is usually administered weekly for 3 subse-
quent weeks in a 28-day cycle.
Cytotoxicity of epirubicin is mainly explained by prevention of
the resealing of topoisomerase-II-mediated cleavable complexes
in DNA and DNA interstrand cross-linking leading to prevention
of replication and transcription and by formation of DNA breaks.
The cytotoxic effect of gemcitabine is related to the incorporation
of its phosphorylated metabolites into DNA, which leads to
impairment of DNA replication and elongation, and inhibition of
DNA polymerases. In vivo, both drugs have a different toxicity
profile and therefore it was anticipated that they could easily 
be combined. Although the Non-Small-Cell Lung Cancer expert
panel of the American Society of Clinical Oncology recommends
cisplatin-based combination chemotherapy regimens in advanced
NSCLC non-platinum-containing regimens should be explored to
find less toxic therapies (American Society of Clinical Oncology,
1997).
Development of an active outpatient regimen with acceptable
toxicity was the rationale for starting our trial with the combina-
tion of epirubicin and gemcitabine in patients with advanced
NSCLC.
PATIENTS AND METHODS
Inclusion criteria
Patients were recruited from four regional hospitals and one
university hospital in the northern part of The Netherlands. The
phase I part of the study was performed only in the university
hospital. Patients were included if they had histological or cyto-
logical diagnosis of unresectable (stage IIIb, who were not eligible
for curative radiotherapy) or disseminated (stage IV) NSCLC.
Patients should not have received prior chemotherapy. Prior radio-
therapy was allowed as long as no more than 25% of red bone
marrow was irradiated, radiotherapy was completed at least 
4 weeks before inclusion, the patient had recovered from any toxic
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measurable disease. All patients had to have Eastern Cooperative
Oncology Group (ECOG) performance status 0–2, an estimated
life expectancy of at least 12 weeks and adequate bone marrow
reserve with leucocytes ³ 3.0 ´ 109 l–1, neutrophils ³ 1.5 ´ 109 l–1,
platelets ³ 100 ´ 109 l–1 and haemoglobin ³ 6.2 mmol l–1. In the
phase II study measurable or evaluable tumour lesions were neces-
sary on physical examination, X-ray or computerized tomography
scan. Patients had to take contraceptive precautions, and females
with childbearing potential had to have a negative pregnancy test.
Patients were excluded if they had active infections, second
primary malignancies (except carcinoma in situ of the cervix,
adequately treated basal cell carcinomas of the skin or curatively
treated upper respiratory tract malignancies with a follow-up of 
at least 3 years), current or prior central nervous system metas-
tases, and a left ventricular ejection fraction (LVEF) measured 
by multiple electrocardiogram (ECG)-gated radionuclide study
(MUGA-scan) lower than 50% (below 90% of the lower normal
limit). Patients were also excluded if they had inadequate liver
function tests defined as serum bilirubin ³ 35 mmol l–1 and/or
serum alanine aminotransferase and aspartate aminotransferase
more than 3 times the upper normal limit, an impaired renal func-
tion defined as a serum creatinine ³ 120 mmol l–1 and uncorrected
hypercalcaemia.
All local medical ethics committees approved the protocol.
Informed consent was obtained from all treated patients.
Treatment and dose adjustments
All cytotoxic agents were administered on an outpatient basis.
Gemcitabine was administered as a 30-min i.v. infusion on days 1
and 8 of each 21-day cycle at a fixed dose of 1125 mg m–2. This
gemcitabine dose leads to a dose intensity of 750 mg m–2 week–1,
which is the same compared to a schedule in which gemcitabine
1000 mg m–2 week–1 is given weekly for 3 consecutive weeks in a
28-day schedule. The nadir of epirubicin is expected 12–15 days
after administration, therefore we omitted gemcitabine on day 15.
Epirubicin was administered afterwards as an i.v. bolus injection
over a period of 5 min on the first day of each 21-day cycle. In 
the phase I study, escalating epirubicin doses of 90, 100 and 
120 mg m–2 were administered. The dose level below the
maximum tolerated dose (MTD) would be used to continue with
the phase II study. Anti-emetics were standardized with
ondansetron 8 mg twice a day on days 1, 2 and 8 and dexametha-
sone 8 mg once before drug administration on day 1, and twice a
day on days 1, 2 and 8 only if necessary. Drug administration was
postponed to a maximum of 2 weeks if there was no full haemato-
logical recovery on day 22 (neutrophils < 1.5 ´ 109 l–1 and/or
platelets < 100 ´ 109 l–1) or in case of persistent CTC grade 2 or
more non-haematological toxicity.
The dose of epirubicin for subsequent cycles was reduced to
75% in case of a persistent nadir of granulocytes below 0.5 ´ 109
l–1 for longer than 5 days, a nadir of platelets below 25 ´ 109 l–1,
thrombocytopenia associated with bleeding, febrile neutropenia or
CTC grade 3 or more non-haematological toxicity. The dose of
gemcitabine at day 8 was reduced to 50% in case of granulocytes
between 0.5 and 1.5 ´ 109 l–1 or platelets between 50 and 100 ´ 109
l–1 or grade 3 non haematological toxicity, and was omitted in case
of granulocytes < 0.5 ´ 109 l–1, or platelets < 50 ´ 109 l–1, or in case
of CTC grade 4 non-haematological toxicity. Treatment consisted
of a maximum of 5 cycles and was stopped in case of tumour
progression, intolerable toxicity or patient’s wish. No other
chemotherapy or experimental medication was permitted while
patients were on study.
Toxicity score
Toxicity was measured according to the Common Toxicity Criteria
(CTC) of the National Cancer Institute. Complete blood cell
counts were measured at least at day 1, 8, 12, 15, 17 and 22 of each
21-day cycle. For the phase II study blood cell counting on day 15
was omitted. During the last week of each cycle evaluation also
included ECG, liver and renal function, tumour measurement and
toxicity scores. LVEF was measured by MUGA scan before and 
6 weeks after treatment.
MTD for phase I study of epirubicin and gemcitabine
The assessment of MTD was based on the first cycle of
chemotherapy. The MTD was reached if any of the following
DLTs occurred in at least two out of three or three out of six
patients: absolute granulocytes < 0.5 ´ 109 l–1 for more than 
7 days, granulocytes < 1.0 ´ 109 l–1 on day 8, febrile neutropenia,
platelets < 50 ´ 109 l–1 on day 8, platelets < 25 ´ 109 l–1 at any
moment during the cycle or thrombocytopenia associated with
bleeding, non-haematological toxicity (excluding alopecia, nausea
and vomiting) CTC grade 3 or 4 at any moment during the cycle,
or persistent grade 2 toxicity at the scheduled start of the next
cycle, or cardiac toxicity as defined by clinical signs and symp-
toms of cardiac failure or an absolute decrease of LVEF detected
by MUGA-scan of more than 15% from baseline or more than
10% to a level below the normal limit (55% for our institutions).
Evaluation of tumour response and quality of life
Evaluation of tumour response was conducted according to stan-
dard World Health Organization (WHO) criteria (WHO, 1979). A
responder was defined as any patient who had a complete or partial
response, which was confirmed by a second evaluation with the
same imaging technique at least 4 weeks later. A complete
response (CR) was defined as the complete resolution of all signs
of known disease. A partial response (PR) was defined as a more
than 50% reduction in the sum of the products of the largest
perpendicular diameters of all measurable and evaluable lesions.
Patients who failed to fulfil the criteria for partial response in the
absence of disease progression were classified as having stable
disease (SD). Progression of disease was defined as an increase of
more than 25% in the sum of the products of the largest perpendic-
ular diameters of all measurable lesions or the occurrence of any
new lesion. Response duration, time to progression and survival
time was measured from the date of initiation of chemotherapy. All
patients who completed at least one cycle of treatment were
analysed for toxicity and response. After discontinuation of treat-
ment, patients were evaluated every 6 weeks to assess time to
progression and overall survival.
Another goal of the study was to estimate the effects of this
cytotoxic treatment on quality of life, especially 6 weeks after the
end of treatment. At the start and end of treatment and also 
6 weeks later, quality of life was measured with a standardized 
and validated questionnaire (i.e. EORTC-QLQ-C30 and LC-13)
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and posted anonymously to the data management of the study
group. This questionnaire describes six functional scales, for
which a higher percentage means a better functional performance.
Also symptoms are scored: a lower score means fewer symptoms.
Statistical analysis
In the phase I part of the study a descriptive analysis of toxicity
was performed. The recommended phase II dose was the dose
level below MTD. Sample size for the phase II part of the study
was defined according to Grant. (Grant et al, 1992). The tumour
response rate in patients treated with this dose is presented as
percentage and 95% confidence interval (CI). Median time to
progression and survival time is calculated according to the
Kaplan–Meier product-limit method, alive patients are censored at
the moment of evaluation. Two-sided paired Student’s t-test is
used to analyse the difference between LVEF before and after
treatment. Quality of life is analysed by ANOVA for the different
functions and symptoms at all three points of measurement.
RESULTS
Phase I study
The phase I study was performed at the university hospital and
included 18 patients; six patients were included in each dose level
of epirubicin. Haematological toxicity observed in the first cycle
of the 3 dose levels is shown in Table 1. The median granulocyto-
penia was short lasting: in the first level 2 days (range 0–3), in the
second level 2 days (range 0–3), and in the third level 4 days
(range 1–5). DLT was febrile neutropenia in three out of six
patients in the highest level. Non-haematological toxicity was
mainly mucositis CTC grade 1 and 2 in six out of 18 and grade 3 in
one out of 18 patients, which was observed in all dose steps. The
MTD of epirubicin was 120 mg m–2 i.v. administered on day 1 in
combination with gemcitabine 1125 mg m–2 i.v. given on days 1
and 8 of a 21-day cycle. We proceeded with the phase II part of 
the study with epirubicin 100 mg m–2 on day 1 and gemcitabine
1125 mg m–2 on days 1 and 8 in a 21-day schedule. In all dose
levels responses were observed, the overall response rate was 
44% and the median survival was 28 weeks.
Phase II study
Patient characteristics
From June 1997 till August 1998, 43 patients were included in five
hospitals in the northern region of The Netherlands. The baseline
characteristics of the patients are shown in Table 2. The median
age was 60 years (range 26–75); the median ECOG performance
status was 1 (range 0–2). Most patients were in stage IV (74%).
Toxicity
The haematological toxicity of a total of 178 cycles is shown in
Table 3. In two-thirds of cycles CTC grade 3 and 4 granulo-
cytopenia developed, which was usually of short duration. Six
patients developed febrile neutropenia, three patients during the
first cycle and three during subsequent cycles. All these patients
recovered after i.v. treatment with antibiotics during hospitaliza-
tion. Of the 43 enrolled patients, 26 received blood transfusion and
seven platelet transfusion. Grade 4 thrombocytopenia occurred in
11.6% of all cycles, which was in 23.2% of patients. Non-haema-
tological toxicity is shown in Table 4. Mucositis grade 2 and 3
occurred in 35% of patients, but was manageable in all patients. In
one patient hospitalization was necessary due to mucositis CTC
grade 3, this patient also developed bleeding from a gastric ulcer 
at the time his platelet count was 12 ´ 109 l–1. One patient was
admitted to the hospital after the fourth cycle for pulmonary
embolism, which responded to i.v. heparin. No treatment-related
deaths were observed. At study entry the mean LVEF measured by
MUGA-scan was 62.3%, after treatment 56.4%. The median
decrease in LVEF was 7.2% (s.e.m. 1.4), which was statistically
significant (paired sample t-test,  P < 0.01), but not of clinical
significance. In three patients (7%) a significant decrease of LVEF
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Table 1. Hematologic toxicity of the first cycle (number of patients) in the
phase I part of the study
CTC-toxicity Leucocytes Granulocytes Haemoglobin Platelets
Level 1
0–2 1 1 5 5
34 2 1 1
41 3 0 0
Level 2
0–2 1 2 6 5
31 1 0 1
44 3 0 0
Level 3
0–2 0 0 6 2
31 2 0 4
45 4 0 0
Escalating doses of epirubicin at day 1 (level 1 = 90 mg m–2, level 2 = 100 mg
m–2, level 3 = 120 mg m–2) with a fixed dose of gemcitabine 1125 mg m–2 at
days 1 and 8, six patients in each dose level.
Table 2 Patient characteristics in the phase II part of the study
Males/females 27/16
Age (years)
Median (range) 60 (26–75)
Stage
IIIa 1
IIIb 10
IV 32
Performance status
01 5
12 0
28
Weight loss
≤ 10 kg in 3 months 36
> 10 kg in 3 months 7
Histology
Squamous cell ca 19
Adenocarcinoma 20
Large cell ca 4
Table 3 Haematologic toxicity in 43 patients in the phase II part of the study
for a total of 178 cycles (% of cycles)
CTC-toxicity Leucocytes Granulocytes Platelets Haemoglobin
0 13.4 14.7 49.4 28.0
1 9.2 3.7 12.8 34.2
2 18.9 15.9 12.2 25.6
3 40.2 33.2 14.0 10.4
4 18.3 32.5 11.6 1.8was observed, but these patients did not show clinical signs of
heart failure during a follow-up period of 11 months.
The median number of cycles administered was 5 (range 2–5);
the maximum of 5 cycles was received by 60% of patients.
Reasons to stop treatment prematurely (n = 17) were: tumour
progression in 12 patients (28%), cardiotoxicity in one patient
after 3 cycles, and recurrent infections in a large cavitating tumour
in one patient during 2 cycles, and sudden death at home after 3
cycles in one patient. Two patients requested to stop treatment
after 4 cycles. One of these patients had a partial response and
good relief of pain caused by bone metastases, but complaints of
CTC grade 3 mucositis. The other patient had stable disease and
complaints of CTC grade 2 asthenia and grade 3 mucositis.
In five patients (12%) dose reduction of epirubicin to 75% was
necessary after the first cycle: in three patients due to febrile
neutropenia and in two patients due to CTC grade 4 thrombo-
cytopenia. In three patients (7%) epirubicin was reduced during
subsequent cycles because of febrile neutropenia in one patient
and grade 4 thrombocytopenia in two patients. In ten patients
(23%) the gemcitabine dosage at day 8 was reduced to 50% in one
or two cycles. Treatment delay for 1 week was necessary in one
patient due to haematology toxicity and in one patient due to a
combination of mucositis and asthenia.
Primary efficacy
Of the 43 patients included in this study, two patients achieved a
complete response and 19 patients a partial response, which
accounts for an overall response rate of 49% (95% CI 35–63%).
Stable disease occurred in 13 patients (33%), including three
patients who showed more than 50% reduction of the primary
tumour but with stable distant metastases. Tumour response rate
for patients with PS 2 was 25% (n = 8). Mean time to disease
progression for all patients was 26 weeks (95% CI 19–33), median
survival was 41 weeks (95% CI 13–69) (Figure 1). The 1-year
survival was 49%. Median survival for patients who responded to
chemotherapy (PR and CR) was significantly longer compared to
non-responding patients (SD and PD) (63 vs 17 weeks, P < 0.01),
1-year survival for responders was 70%. Median survival for
patients in stage IV was 55 weeks (95% CI 11–99) and 1-year
survival was 50%. Median survival for patients with PS 2 was 24
weeks (95% CI 10–38) compared to 55 weeks (95% CI 26–84) for
PS 0 and 1. No statistically significant differences in survival and
tumour response rate were observed according to sex, stage,
performance score and pretreatment weight loss. Fifty-one per
cent of patients had local tumour progression or progression of
already existing metastases, while 30% developed new metastases
as the first manifestation of progression. In 19% of patients no
progression was observed till the moment of evaluation, which is
at least 4 months after the end of treatment. None of the patients
with liver metastases responded to treatment (n = 6).
Supportive therapy
Only one patient in stage IIIb achieved 60 Gy radiotherapy to the
primary tumour, the mediastinum and supraclavicular lymph
nodes after reaching a near complete response after 5 cycles.
During the study radiotherapy was not needed to relieve patients’
complaints. None of the patients was treated with second-line
chemotherapy till the moment of evaluation. All patients received
prophylactic anti-emetics with ondansetron, in only four patients
dexamethasone and metoclopramide were additionally prescribed.
Treatment for mucositis with lidocaine gel and Candida stomatitis
with oral fluconazole or amphotericin was administered in 53% of
patients.
Quality of life
Only 28 patients returned their quality of life questionnaires. The
number of dropouts for the second and third measurement was 
7 and 11 respectively. No significant changes of functional and
symptom scales were observed at any time of measurement for the
individual patients and for the mean and median of the groups. No
correlation was observed between tumour response and changes in
quality of life scores. Patients who have returned their question-
naires and those who did not were not different with respect to
median survival.
DISCUSSION
The results of four recently published meta-analyses indicate 
that cisplatin-based chemotherapy results in an improvement in
median survival of 10 weeks in patients with stage IV NSCLC
(Souquet et al, 1993; Marino et al, 1994; NSCLC Collaborative
Group, 1995; Lilenbaum et al, 1998). However, in these meta-
analyses the efficacy of newer, probably more active drugs were
not included. Compared to newer active drugs in NSCLC single-
agent treatment with cisplatin showed in more recent trials only
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Table 4 Non-haematologic toxicity in the phase II part of the study (number
of patients)
CTC-toxicity Nausea Mucositis Phlebitis Asthenia Rash
01 9 1 9 3 2 9 3 7
11 9 9 9 2 2 3
25 1 3 2 1 2 3
30 2 0 0 0
40 0 0 0 0
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Figure 1 Kaplan–Meir curve for survival in 43 patients with advanced
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low response rates of about 10% (Bunn, 1989; Sandler et al, 1998).
On the other hand, addition of cisplatin to a number of cytotoxic
drugs seems to lead to synergistic anti-tumour effects.
Disadvantages of the administration of cisplatin are its toxicity and
the use of hydration schedules, which will often necessitate hospi-
talization.
High-dose single-agent epirubicin is effective in NSCLC (Wils
et al, 1990; Smit et al, 1992). In our institution, prior research was
performed on the efficacy of high-dose epirubicin in advanced
NSCLC (Smit et al, 1992; Bakker et al, 1995). We were searching
for another drug to combine with epirubicin to develop an active
combination in advanced NSCLC, which could be administered
without hospitalization. Single-agent gemcitabine has shown a
relatively mild toxicity profile and is an active single-agent in the
treatment of advanced NSCLC (Abratt et al, 1994; Gatzemeier et
al, 1996). Epirubicin as well as gemcitabine can easily be adminis-
tered in an outpatient regimen and have a different toxicity profile,
except thrombocytopenia.
Given the same efficacy of several cytotoxic regimens in
NSCLC a comparison of drug toxicity is important for these pallia-
tive regimens. Excluding patients with progressive disease, most
patients (84%) received the maximum of 5 cycles, which indicates
the mild toxicity of our regimen. Haematological toxicity of our
regimen was modest and dose reductions were not often necessary.
However, CTC grade 2 and 3 mucositis is the most troublesome
non-haematological toxicity, which appeared in 35% of patients.
This incidence may be decreased with better preventive strategies
and immediate treatment in case of developing oral mucositis
(Wilkes, 1998).
Cardiotoxicity measured as a significant decrease of LVEF was
observed in 7% of patients, who were, however, treated with not
more than 500 mg m–2 epirubicin. This percentage is not signifi-
cantly different from the 8 and 16% incidence described by other
authors (Feld et al, 1992; Smit et al, 1992). We did not observe
clinical overt signs of heart failure. Mediastinal radiotherapy and
use of other cardiotoxic agents may predispose patients to
cardiotoxicity at lower cumulative epirubicin doses. In our study
only three patients had received prior mediastinal radiotherapy, of
which one showed a significant decrease in LVEF.
Because cytotoxic treatment in patients with advanced NSCLC
is not curative, patients’ quality of life and improvement of symp-
toms is especially important. However, quality of life is difficult to
define precisely, describing a sense of well-being which includes
several different factors such as physical functioning and symp-
toms, social interaction, psychological well-being and economic
aspects. A tumour response to chemotherapy in NSCLC can lead
to symptom relief and thereby improvement of quality of life
(Cullen, 1993; Billingham et al, 1997). In our study we could not
find significant differences in the quality of life and symptoms
before and after treatment. Unfortunately only 65% of patients
returned the first questionnaires and a relatively large number of
dropouts is observed at the other points of evaluation. Therefore
we are not able to draw firm conclusions. However, our findings
seem consistent with the results of quality of life analysis in
patients treated with cisplatin and gemcitabine, which also showed
no differences before and after treatment (Cardenal et al, 1999).
Only a few non-platinum-containing regimens are known to be
active in NSCLC. One study has reported that the addition of
cisplatin to the combination of epirubicin and ifosfamide did not
change its effectiveness, in terms of tumour response rates and
survival (Brocato et al, 1995). Other active combinations in
NSCLC without a platinum compound are developed, e.g. gem-
citabine and paclitaxel (Georgoulias et al, 1999). The combination
of cisplatin and gemcitabine has been evaluated in NSCLC in
several phase II and phase III trials reporting response rates of
31–54% and a median survival of 8.4–14.3 months (Sandler et al,
1995, 1996, 1998; Abratt et al, 1997; Crino et al, 1997, 1998;
Anton et al, 1998; Cardenal et al, 1999). Whether addition of
epirubicin to gemcitabine is comparable to the combination of
cisplatin and gemcitabine in terms of survival, quality of life and
cost-effectiveness will be further evaluated in a randomized phase
III study we have recently initiated.
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